Carolien C.H.M. Maas

About me
Publications
Public outreach and news

About me

I am a postdoctoral researcher with dual affiliations at the Leiden University Medical Center and the Karolinska Institutet. My background is in econometrics, and my doctoral research at Erasmus University Rotterdam centred on applying and developing methodological approaches for prediction modelling in oncology (Methods for prediction in cancer: prognosis and treatment effects - Erasmus University Rotterdam). At present, I collaborate with dr. Edouard L. Fu on research in causal inference within the field of nephrology.

Articles

Journal article: CLINICAL TRANSPLANTATION. 2025;39(9):e70299
A Comprehensive Assessment of Plasma CXCL9 and CXCL10 in Improving Clinical Prediction Models for Kidney Allograft Rejection.
Souza AAD; Hesselink DA; Maas CCHM; Stubbs AP; Clahsen-van Groningen M; Baan CC; Klaveren DV; Boer K
Journal article: BJS-BRITISH JOURNAL OF SURGERY. 2025;112(4):znaf037
External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy.
Stassen RC; Maas CCHM; Leong SP; Kashani-Sabet M; White RL; Pockaj BA; Zager JS; Schneebaum S; Vetto JT; Avisar E; Harrison Howard J; O'Donoghue C; Kosiorek H; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ; Olofsson Bagge R
Journal article: BMC HEALTH SERVICES RESEARCH. 2024;24(1):1469
Identifying persistent high-cost patients in the hospital for care management: development and validation of prediction models.
de Ruijter UW; Kaplan ZLR; Eijkenaar F; Maas CCHM; van der Heide A; Bax WA; Lingsma HF
Journal article: BLOOD CANCER JOURNAL. 2024;14(1):157
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.
Maas CCHM; van Klaveren D; Durmaz M; Visser O; Issa DE; Posthuma EFM; Zijlstra JM; Chamuleau MED; Lugtenburg PJ; Kersten MJ; Dinmohamed AG
Journal article: BMC MEDICAL RESEARCH METHODOLOGY. 2024;24(1):176
Pitfalls of single-study external validation illustrated with a model predicting functional outcome after aneurysmal subarachnoid hemorrhage.
de Winkel J; Maas CCHM; Roozenbeek B; van Klaveren D; Lingsma HF
Journal article: BMJ PUBLIC HEALTH. 2024;2(1):e000470
Disability weights for environmental noise-related health states: results of a disability weights measurement study in Europe.
Charalampous P; Maas CCHM; Haagsma JA
Journal article: LANCET ONCOLOGY. 2024;25(4):509-517
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ
Journal article: EBIOMEDICINE. 2024;102:105072
Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome.
van Tilburg SJ; Teunissen CE; Maas CCHM; Thomma RCM; Walgaard C; Heijst H; Huizinga R; van Doorn PA; Jacobs BC
Journal article: STATISTICS IN MEDICINE. 2023;42(24):4514-4515
Measuring the performance of prediction models to personalize treatment choice: Defining observed and predicted pairwise treatment effects.
van Klaveren D; Maas CCHM; Kent DM
Journal article: BMC MEDICAL RESEARCH METHODOLOGY. 2023;23(1):165
Performance metrics for models designed to predict treatment effect.
Maas CCHM; Kent DM; Hughes MC; Dekker R; Lingsma HF; van Klaveren D
Journal article: ECLINICALMEDICINE. 2023;60:101994
Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989-2019.
Maas CCHM; van Klaveren D; Visser O; Merkx MAW; Lingsma HF; Lemmens VEPP; Dinmohamed AG
Journal article: LEUKEMIA. 2022;36(5):1416-1420
Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.
Dinnessen MAW; Maas CCHM; Tonino SH; Visser O; Posthuma EFM; Blijlevens NMA; Kersten MJ; Lugtenburg PJ; Dinmohamed AG
Journal article: BLOOD CANCER JOURNAL. 2022;12(4):72
Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018.
van der Straten L; Maas CCHM; Levin M-D; Visser O; Posthuma EFM; Doorduijn JK; Langerak AW; Kater AP; Dinmohamed AG
Journal article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;196(5):1219-1224
The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
Maas CCHM; van Klaveren D; Ector GICG; Posthuma EFM; Visser O; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG

All other publications

Preprint: MEDRXIV. 2025;MEDRXIV
Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH Statement.
Selby JV; Maas CCHM; Fireman BH; Kent DM
Preprint: MEDRXIV. 2024;MEDRXIV
Quantifying absolute treatment effect heterogeneity for time-to-event outcomes across different risk strata: divergence of conclusions with risk difference and restricted mean survival difference.
Maas CCHM; Kent DM; Dinmohamed AG; van Klaveren D
Preprint: MEDRXIV. 2022
Performance metrics for models designed to predict treatment effect
Maas CCHM; Kent DM; Hughes MC; Dekker R; Lingsma HF; van Klaveren D

About me

Articles

All other publications

News from KI

Events from KI